Ekso Bionics Holdings Inc. news has covered its exoskeleton technology business for medical and industrial applications, including robotic systems designed to support mobility, strength, endurance, and rehabilitation. Company updates include financial results, product and distribution activity, sales trends for Enterprise Health devices and Ekso Indego Personal devices, and rehabilitation offerings such as MediTouch’s BalanceTutor system and eksoUniversity continuing education courses.
Recurring corporate developments also include material agreements, shareholder voting matters, capital-structure disclosures, governance actions, and the completed formation of ChronoScale through a strategic combination involving EKSO Bionics.
ChronoScale (CHRN) signed two AI infrastructure agreements supporting an expected annualized revenue run rate of $1 billion by calendar Q3 2027.
The agreements extend an existing customer contract and add a new customer, expanding the contracted deployment pipeline and capacity. The revenue expectation includes existing contracts and the current deployment schedule; it is not revenue already earned. Achievement and timing depend on infrastructure deployment and commissioning, power and equipment availability, and access to capital on acceptable terms.
ChronoScale also completed the sale of its Ekso Bionics business unit. The company believes the divestiture will concentrate operations, management resources and capital allocation on accelerated computing and AI infrastructure.
ChronoScale (NASDAQ: CHRN) announced plans with Microsoft for a 50-megawatt (MW) AI compute deployment in North America, built around NVIDIA GB300 NVL72 systems and advanced liquid-cooling. The planned full-stack infrastructure combines compute, networking, storage, software, and purpose-built data center design to support high-density AI training and inference workloads. According to ChronoScale, the integrated platform is intended to meet next-generation accelerated computing requirements for power, cooling, and operations while aiming to deliver production-ready AI capacity for developers and enterprises.
ChronoScale (NASDAQ: CHRN) appointed Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to advance its global AI infrastructure strategy. The leaders bring deep experience in AI infrastructure, cloud, and large-scale GPU deployments to support ChronoScale’s accelerated compute platform for enterprises and hyperscalers.
ChronoScale (NASDAQ: CHRN) appointed Cenly Chen as Chief Executive Officer and board member effective May 6, 2026. Chen brings 20+ years of enterprise infrastructure and high-performance computing experience, most recently as Chief Growth Officer and SVP at Super Micro Computer. The company says Chen will lead capacity expansion and operational execution for AI compute.
ChronoScale operates GPU-based infrastructure after combining Applied Digital’s cloud business and EKSO Bionics, focused on AI training, inference, and high-performance computing.
Ekso Bionics (Nasdaq: EKSO) priced a private placement announced Jan 21, 2026 to sell 5,852 shares of Series B preferred stock and warrants to buy up to 355,960 common shares. The preferred has a stated value of $1,000 per share and converts into 711,922 common shares at a conversion price of $8.22. Warrants are exercisable at $8.22, expire five years after initial exercise, and initial exercise begins six months after closing. Gross proceeds are expected to be about $5.9 million; net proceeds will be used for working capital and general corporate purposes.
Ekso Bionics (Nasdaq: EKSO) announced an exclusive U.S. distribution agreement with MediTouch to act as the authorized sales agent and distributor for the BalanceTutor™ rehabilitation system in the United States, dated December 4, 2025.
The BalanceTutor uses a patented 4D perturbation treadmill with multiple force and movement sensors to simulate slips, trips, and stumbles while supporting patient weight via an overhead frame to promote safe reactive balance training in inpatient and outpatient rehabilitation settings.
Ekso said the product is complementary to its enterprise health exoskeleton offerings and will be marketed through its existing customer call points to increase awareness and adoption across U.S. physical rehabilitation facilities.
Ekso Bionics (Nasdaq: EKSO) announced a registered direct offering entered on October 28, 2025 to sell 769,490 shares of common stock at $4.81 per share in an at-the-market transaction under Nasdaq rules.
The offering is expected to close on or about October 30, 2025, with gross proceeds of approximately $3.7 million before placement agent fees and other offering expenses. Lake Street Capital Markets is the exclusive placement agent.
The company intends to use net proceeds for general corporate purposes, including research and development, selling, general and administrative costs, strategic initiatives and working capital. The shares are being offered under a Form S-3 shelf registration declared effective June 20, 2023.
Ekso Bionics (Nasdaq: EKSO) reported Q3 2025 results on Oct 28, 2025: revenue $4.2M (up 2% YoY, up 105% sequentially), gross margin 60.3% (up 680 bps YoY, driven by higher Enterprise Health sales and lower device cost), and net loss $1.4M (improved 31% YoY, $0.54 per share). Operating expenses declined across S&M, R&D and G&A mainly due to Employee Retention Credit benefits.
The company had $2.7M cash at Sept 30, 2025 and announced it is exploring strategic transactions, which may include divestiture or acquisition and could require substantial issuance of company securities.
Ekso Bionics (NASDAQ: EKSO), a leader in exoskeleton technology, reported its Q2 2025 financial results, showing significant challenges. Revenue declined to $2.1 million from $5.0 million in Q2 2024, primarily due to lower Enterprise Health device sales. The company posted a net loss of $2.7 million, or $1.24 per share.
Despite challenges, Personal Health products grew over 50% year-over-year in H1 2025. Notable developments include naming Bionic P&O as first Ekso Indego Personal device distributor, joining NVIDIA Connect program for AI development, launching an AI voice agent for EksoNR, and introducing eksoUniversity for physical therapy education.
Gross margin decreased to 40% from 53% year-over-year, while cash position stood at $5.2 million as of June 30, 2025.
Ekso Bionics (NASDAQ:EKSO), a leader in medical and industrial exoskeleton technology, has scheduled its Q2 2025 financial results release for July 28, 2025 after market close. The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss financial performance and recent business developments.
Investors can join via phone by dialing 877-407-6184 (domestic) or 201-389-0877 (international). The presentation will also be available through a live webcast and archived on the company's investor relations website.